NORTH LIBERTY, Iowa, Aug. 28, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present a poster on KP201 at PAINWeek 2013, the nation's largest pain conference for frontline clinicians with an interest in pain management.
The poster, entitled "KP201: A Novel Opioid Pain Therapy with Reduced Abuse Potential and Improved Safety," will be displayed on September 6, 2013 between 6:15 PM and 7:30 PM, PDT and will detail KP201's clinical studies and unique abuse-deterrent properties, which have been shown to significantly limit narcotic exposure upon intranasal administration and intravenous injection. Additionally, the poster will highlight the potential for KP201 to prevent or reduce opioid-induced constipation (OIC).
Dr. Mickle commented, "Showcasing KP201 at PAINWeek 2013 provides an opportunity for clinicians with an interest in pain management to gain an understanding of the drug's advantages and its potential as a future treatment option for their patients. We welcome the opportunity to present what we believe is very compelling data on KP201 that highlight not only its ability to treat pain but the added benefit of a reduction in abuse potential and opioid-induced constipation."
About KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases. KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD. For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Christal Mickle
email@example.comJason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
|SOURCE KemPharm, Inc.|
Copyright©2012 PR Newswire.
All rights reserved